Morphic Holding, Inc.

NASDAQ (USD): Morphic Holding, Inc. (MORF)

Last Price

27.99

Today's Change

+0.48 (1.74%)

Day's Change

27.12 - 28.15

Trading Volume

371,129

Overview

Market Cap

1 Billion

Shares Outstanding

50 Million

Avg Volume

498,944

Avg Price (50 Days)

34.26

Avg Price (200 Days)

35.92

PE Ratio

-7.80

EPS

-3.59

Earnings Announcement

23-Apr-2024

Previous Close

27.51

Open

27.27

Day's Range

27.12 - 28.15

Year Range

19.345 - 63.083

Trading Volume

371,129

Price Change Highlight

1 Day Change

1.74%

5 Day Change

-2.06%

1 Month Change

-19.22%

3 Month Change

5.07%

6 Month Change

36.07%

Ytd Change

-3.25%

1 Year Change

-37.55%

3 Year Change

-51.41%

5 Year Change

55.50%

10 Year Change

55.50%

Max Change

55.50%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment